Prokidney Corp. (NASDAQ:PROK)
| Market Cap | $349.70M-51.4% |
| Revenue (ttm) | $775.00K+4.2% |
| Net Income | -$103.28M-45.4% |
| EPS | -$0.60-9.1% |
| Shares Out | 148.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,901,121 |
| Open | $1.03 |
| Previous Close | $1.06 |
| Day's Range | $1.02 - $1.08 |
| 52-Week Range | $0.87 - $2.65 |
| Beta | 1.90 |
| Analysts | Buy |
| Price Target | $4.67(+349.04%) |
| Earnings Date | Mar 17, 2027 |
About PROK
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating PROK in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 17, 2027Earnings report
$PROK stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PROK holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PROK's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PROK Estimated quarterly lobbying spending
Source: U.S. Senate LDA
PROK Revenue by Segment
| Equity-based compensation | $16.42M | 98.95% |
| Rental income | $174.00K | 1.05% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New PROK patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PROK from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PROK
| IWMiShares Russell 2000 ETF | $2.84M |
| VXFVanguard Extended Market ETF | $2.24M |
| SCHASchwab U.S. Small-Cap ETF | $869.52K |
| VTWOVanguard Russell 2000 ETF | $833.13K |
| IWOiShares Russell 2000 Growth ETF | $732.59K |
| SURISimplify Propel Opportunities ETF | $503.09K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from PROK’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings miss on revenue coupled with reported loss outweighs leadership appointment; concrete negative business results dominate coverage.
